|
Source:Forbes Blogs by Robert Langreth and Rebecca Ruiz Aug. 30 2010 - 9:50 am
Alexsandra Wixom started experiencing uncontrollable bouts of sadness when she was 15. “I was emotionally off. I cried all the time,” recalls the Seattle-area resident, who is now 25. Her mood swings eventually became so wild the former honors student had to quit going to high school. Over the next eight years she saw a psychiatrist every other week. Her doctors tried everything from Zoloft to mood stabilizers to heavy-duty antipsychotics, but none of them helped for long.
<snip>
Few suicidal patients get such good treatment. Roughly 35,000 Americans commit suicide each year–more than die from prostate cancer or Parkinson’s disease. Another 1.1 million people make attempts, while 8 million have suicidal thoughts. Among those aged 15 to 25 it is the third leading cause of death. Yet researchers know astonishingly little about how to treat people who contemplate killing themselves. The subject has been so roundly ignored that the 900-page bible of psychiatry, the Diagnostic and Statistical Manual of Mental Disorders IV, offers no advice for doctors on how to assess suicide risk.
Fear, logistics, low research funding and more risk than reward for drug companies all conspire to make suicide the neglected disease. The National Institutes of Health is spending a paltry $40 million in 2010 studying suicide, versus $3.1 billion for research on aids, which kills half the number of Americans. (Another government agency spends $48 million on hotlines and prevention.) Therapists often don’t want to treat suicidal patients, and university clinical study review boards are skittish about studying them, says the University of Washington’s Linehan.
Big pharma routinely excludes suicidal patients from their tests of antidepressants and other drugs. There’s no commercial imperative to crawl out on that limb. Trials in at-risk patients would cost millions of dollars and could take years to perform; they might yield murky results–or worse. A suicide in the drug group could be used by competitors to destroy even a promising drug. The legal overhang is real. GlaxoSmithkline has paid $390 million to settle lawsuits related to patients who attempted or completed suicide while on Paxil, Bloomberg News estimates.
<more at link, emphasis added>
________________________________________________________________________
I don't want to make this a tangential bashing of big pharma: I think we can simply stipulate that they are cowardly and narrowly self-interested.
The medical research community fares little better. Clueless, overwhelmed, and underfunded, most have chosen any other research field where they feel more immediate progress can be made. For every valuable study, there are a dozen fraught with puzzles, nonsense, and weak correlations. A few are doing pioneering work, and they will be pointed out later.
Nor is there much wisdom about the causes or prevention suicide in our culture. It would take volumes to list the myths and misconceptions. About all we can say with any certainty is that it is the result of either trauma, one of three mental illnesses, and to some degree social isolation. There are a few drugs which might be effective, otherwise the best advice is usually some version of "stay close, talk often", but neither is a guarantee. Illness research advocacy groups are politically weak in comparison to, for example, cancer survivors groups. Frankly, I think about all the surviving relatives can manage is their own recovery, and community activism is usually beyond their reach.
I'll post the other parts in the next few days. Hope to reach more people that way.
A note to parents with children aged 18, especially those college bound:They may not legally drink and some colleges feel obliged to send you their grades, but their medical records become private at that point. You will not be informed of the diagnosis of a potentially fatal illness, an illness which by definition renders the sufferer incapable of clear thinking.
|